Novo Nordisk Reports About 21% Weight Loss With Lower-Dose CagriSema
Novo Nordisk said its investigational obesity treatment CagriSema achieved estimated average weight loss of approximately 21% in Phase III REDEFINE 9 trials.
Novo Nordisk said its investigational obesity treatment CagriSema achieved estimated average weight loss of approximately 21% in Phase III REDEFINE 9 trials.